Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.

Abstract: An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2?Z,3?E)-6-bromoindirubin-3?-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.

Abstract: An RNAi molecule that can selectively and effectively suppress only the expression of a particular dominant mutant gene, while permitting the expression of the wild-type gene or a desired mutant gene, and a design method thereof is presented.

Abstract: In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.

Abstract: The invention provides a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy that is capable of measuring multiple cartridges. The apparatus includes a device for setting up multiple cartridges and a device for measuring the radiation intensities of radiation passing through a narrow slit. Radiation is emitted from multiple radiation sources and the radiation measurement device moves simultaneously together with the slit along with the side of cartridge holding device while scanning the radiation intensities. Included is a radiation detection scanning device for measuring radiation intensities for each of the radiation sources passing through the narrow slit, and a slit shielding system for restricting radiation originated originating from both the side neighboring radiation sources.

Abstract: Provided is a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy capable of measuring multiple cartridges efficiently and rapidly.

Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.

Abstract: In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of biliary tract cancer. As a result, in-frame fusion transcripts between the FGFR2 gene and other gene (BICC1 or AHCYL1 gene) were identified. It was also found that said gene fusions induce activation of FGFR2 protein, thereby causing canceration of cells. Further, it was demonstrated that the FGFR2 protein activation and canceration caused by said gene fusions can be suppressed by using an FGFR2 inhibitor, and that treatments with an FGFR2 inhibitor are effective in patients with detection of said gene fusions.

Abstract: In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of diffuse-type gastric cancer. As a result, in-frame fusion transcripts between the CEP55 gene and the RET gene were identified. It was also found that said gene fusions induce activation of RET protein, thereby causing canceration of cells. Further, it was demonstrated that the RET protein activation and canceration caused by said gene fusion can be suppressed by using a RET tyrosine kinase inhibitor, and that treatments with a RET tyrosine kinase inhibitor are effective in patients with detection of said gene fusion.

Abstract: The present invention provides; a novel gene introduction method which enables a gene to be introduced more safely and more freely, particularly a method for introducing a gene into a specified site in the brain safely and freely; a carrier for gene introduction use, which comprises a nano-particle and a substance capable of binding to a vector for gene introduction and has functional groups involved in the induction of phagocytosis by cells, wherein the substance capable of binding to a vector for gene introduction can bind to the surface of the nano-particle through some of the functional groups and another some of the functional groups remain unbound to the substance capable of binding to a vector for gene introduction; and a gene introduction agent, in which a vector for gene introduction is bound to the substance capable of binding to a vector for gene introduction in the carrier for gene introduction.

Abstract: The present invention relates to a method of obtaining a cell population containing cancer stem cells, which comprises culturing iPS cells in the presence of culture supernatant of cancer cells.

Abstract: The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing Aggrus epitope that includes an amino-acid sequence represented by a sequence ID 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with accession number of FERM BP-11446, FERM BP-11447, FERM BP-11448 or FERM BP-11449. The present invention provides the hybridoma, and further an Aggrus-CLEC-2 binding inhibitor and a pharmaceutical composition for inhibition of platelet aggregation, prevention of cancer metastasis, or treatment of tumor or cancer, including the monoclonal antibody or the functional fragment thereof.

Abstract: The present invention provides a method for detecting rhabdomyosarcoma comprising evaluating expression of at least one kind of miRNA selected from the group consisting of hsa-miR-1, hsa-miR-133a, hsa-miR-133b, and hsa-miR-206 in a sample derived from body fluid.

Abstract: The present invention provides a method for producing iPS cells, comprising reacting cells with at least one connexin inhibitor and at least one TGF? signaling inhibitor; iPS cells comprising at least one connexin inhibitor; an iPS cell inducer comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors; a medium for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors; and a kit for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors.

Abstract: An agent for selectively suppressing the expression of a dominant allele while allowing expression of wild-type or desired alleles and methods for using the agent are described. The RNAi agent has a structure obtained by assigning a dominant point mutation in the targeted allele as a standard point, setting a base length from the standard point to the 5? end to a predetermined length, and introducing one mismatch base differing from the target sequence to a predetermined position downstream from the standard point.

Abstract: The present invention addresses the problem of providing an AIDS vaccine whereby mucosal immunity can be induced, the immune system can be defended against breakdown by HIV infection, HIV can be prevented from escaping the immune system by being highly mutable, and rapid HIV infection can be prevented. According to the present invention, provided is an AIDS vaccine comprising a hub antigen and a complex of N2,N6-bis [N2,N6-bis(3,4,5-trihydroxybenzoyl)-L-lysyl]-N-(2-aminoethyl)-L-lys-inamide (TGDK) and fetuin.

Abstract: Provided are: a method for detecting bladder cancer with high detection sensitivity, which has a high specificity for bladder cancer and is capable of detecting bladder cancer tissues with low grade of malignancy; and a bladder cancer marker. A method for detecting bladder cancer cells, which comprises detection of the amount of expressed bladder cancer marker in a subject sample collected from a subject, said bladder cancer marker being composed of one or more miRNAs selected from among miR-124, miR-9 and miR-137; a primer which is used in the method for detecting bladder cancer cells; and a bladder cancer marker.

Abstract: The invention provides a cytotoxic T lymphocyte inducer comprising a virus-like particle composed of VP1 of simian virus 40. The T cell epitope peptide is inserted into a DE loop and/or an HI loop of the VP1.

Abstract: In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.

Abstract: An object of the present invention is to provide a method of producing intestinal cells by use of pluripotent stem cells as a starting material. According to the present invention, provided is a method of producing intestinal cells, comprising the steps of: (A) inducing differentiation of pluripotent stem cells into definitive endoderm cells; and (B) culturing the definitive endoderm cells in the presence of (2?Z,3?E)-6-bromoindirubin-3?-oxime (BIO) and N-[(3,5-difluorophenyl)acetyl]-L-Ala-2-phenyl-L-Gly-tert-butyl-OH (DAPT) to thereby induce differentiation of the definitive endoderm cells into intestinal cells.